Dianicline

Summary

Dianicline (CHEMBL187927) is a phase-3 clinical-stage small molecule; indicated across 1 condition including nicotine dependence.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Indications: 1 condition
• Clinical trials: 1
• Chemistry: 216.28 Da · C13H16N2O

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL187927
Name	Dianicline
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	10176764
Molecular formula	C13H16N2O
Molecular weight	216.28
InChIKey	SUPRUPHAEXPGPF-QWHCGFSZSA-N

SMILES: C1CN2CC[C@@]3(C2)[C@H]1OC4=C(C3)N=CC=C4

IUPAC name: (1R,10S)-9-oxa-4,13-diazatetracyclo[11.2.1.01,10.03,8]hexadeca-3(8),4,6-triene

Also known as: Dianiclina, Dianicline, SSR-591813, SSR591813, DIANICLINE

Patent coverage: 34 distinct patent families (78 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 49 (63%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 disease in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
nicotine dependence	3	MONDO:0008575	EFO:0003768

Clinical trials

Total trials: 1.

Phase distribution

Phase	Trials
PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00356967	PHASE3	COMPLETED	Efficacy and Safety of Dianicline Versus Placebo as an Aid to Smoking Cessation

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).